Autoimmune Collaboration and Licensing Deals 2016-2024


Autoimmune Collaboration and Licensing Deals | Global coverage | Deal financials | Contract documents | Deal trends | Leading dealmakers | Collaboration, licensing, development, and research deals |Comprehensive deal directory 2016 to 2024

Publication date
April 2024
Number of pages
Product type
Research report
Report edition

Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of 882 autoimmune deals from 2016 to 2024.

The report includes coverage of the following autoimmune diseases:

Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn’s disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison’s disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred – contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of autoimmune dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in autoimmune dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the autoimmune field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in autoimmune dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of autoimmune deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of autoimmune deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in autoimmune deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.


Key benefits

Autoimmune Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse autoimmune collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time


Report scope

Autoimmune Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of autoimmune trends and structure of deals entered into by leading biopharma companies worldwide.

Autoimmune Collaboration and Licensing Deals includes:

  • Trends in autoimmune dealmaking in the biopharma industry
  • Overview of collaboration and licensing deal structure
  • Directory of autoimmune deal records covering pharmaceutical and biotechnology
  • The leading autoimmune deals by value
  • Most active autoimmune licensing dealmakers

In Autoimmune Collaboration and Licensing Deals, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Therapeutic area
  • Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.

Autoimmune Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Autoimmune Collaboration and Licensing Deals provides the reader with the following key benefits:

  • Understand deal trends since 2016
  • Browse autoimmune collaboration and licensing deals
  • Benchmark analysis – identify market value of transactions
  • Financials terms - upfront, milestone, royalties
  • Directory of deals by company A-Z, therapy focus and technology type
  • Leading deals by value
  • Most active dealmakers
  • Identify assets and deal terms for each transaction
  • Access contract documents - insights into deal structures
  • Due diligence - assess suitability of your proposed deal terms for partner companies
  • Save hundreds of hours of research time

Executive Summary


Chapter 1 – Introduction


Chapter 2 – Trends in autoimmune dealmaking


2.1. Introduction

2.2. Autoimmune deals over the years

2.3. Autoimmune deals by deal type

2.4. Autoimmune deals by industry sector

2.5. Autoimmune deals by stage of development

2.6. Autoimmune deals by technology type


Chapter 3 – Financial deal terms for autoimmune deals


3.1. Introduction

3.2. Disclosed financials terms for autoimmune deals

3.3. Autoimmune deal headline values

3.4. Autoimmune deal upfront payments

3.5. Autoimmune deal milestone payments

3.6. Autoimmune deal royalty rates


Chapter 4 – Leading autoimmune dealmakers and deals


4.1. Introduction

4.2. Most active in autoimmune dealmaking

4.3. List of most active dealmakers in autoimmune

4.4. Top autoimmune deals by value


Chapter 5 – Autoimmune deal contract document directory


5.1. Introduction

5.2. Autoimmune partnering deals where contract document available


Chapter 6 – Autoimmune dealmaking by therapeutic target


6.1. Introduction

6.2. Deals by autoimmune therapeutic target


Deal Directory


Deal Directory – Autoimmune deals by company A-Z 2016 to 2024

Deal Directory – Autoimmune deals by technology type 2016 to 2024


Deal type definitions


About Biopharma Research Ltd


Current Partnering

Current Agreements

Recent report titles from Current Partnering






Figure 1: Autoimmune deals since 2016

Figure 2: Autoimmune deals by deal type since 2016

Figure 3: Autoimmune deals by industry sector since 2016

Figure 4: Autoimmune deals by stage of development since 2016

Figure 5: Autoimmune deals by technology type since 2016

Figure 6: Autoimmune deals with a headline value

Figure 7: Autoimmune deals with upfront payment values

Figure 8: Autoimmune deals with milestone payment

Figure 9: Autoimmune deals with royalty rates

Figure 10: Active autoimmune dealmaking activity– 2016 to 2024

Figure 11: Top autoimmune deals by value since 2016

Pricing options

  • $3,995: single-user (encrypted file - one user/device)
  • $5,995: multi-user (encrypted file - up to 5 users/devices)
  • $9,995: company (unencrypted file)

Single and Multi-user license files are encrypted PDF documents. Details of how to access using Javelin3 PDF Reader will be provided at report delivery.

Company license files are not encrypted and can be accessed using a PDF Reader.

A full explanation of license type definitions can be found here.


Our guarantee


Price promise

We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.


Delivery Deadline

We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)


Latest report

If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.


Serious Security

We take your data and security seriously. See our privacy policy for details of how we manage your data.

All card payments are processed by Evalon.


Sales Support

If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.

2seventy bio, 3Derm Systems, 4P-Pharma, 4P Therapeutics, 4SC, 9 Meters Biopharma, AB Biosciences, Abbott Laboratories, Abbvie, Abreos Biosciences, AbSci, Abzena, AC Bioscience, Accelerated Cure Project for MS, Accord Healthcare, Acelyrin, Aclaris Therapeutics, Acrobat Genomics, Acrotech Biopharma, Acucela, Aculys Pharma, AdAlta, Adare Pharma Solutions, Adhera Therapeutics, Adimune, Adiso Therapeutics, Aduro BioTech, Adynxx, Aequus Pharmaceuticals, AeroRx Therapeutics, Aerpio Pharmaceuticals, Aevi Genomic Medicine, Affibody, AffyXell Therapeutics, AGC Biologics, AgeX Therapeutics, AgomAb Therapeutics, AHN Autoimmunity Institute, AIMA Laboratories, AimedBio, Akaal Pharma, Akebia Therapeutics, Akouos, Akston Biosciences, Alba Therapeutics, Alexion Pharmaceuticals, Alex Therapeutics, Alfasigma, Alimentiv, Alimera Sciences, Alivio Therapeutics, Alkermes, Allakos, Allegheny General Hospital, Allegheny Technologies, Allen Institute for Immunology, Allergan, Alliance for Lupus Research, Allogene Therapeutics, Alma Bio Therapeutics, Almirall, Alpha Cancer Technologies, Alpine Immune Sciences, AltaVoice, ALTuCELL, Alvit LCS Pharma, Alvotech, Amarna Therapeutics, Ambiopharm, Ambry Genetics, Amegabiotech, American College of Chest Physicians, American Lung Association, American National Multiple Sclerosis Society, American Skin Association, Amgen, Amneal Pharmaceuticals, AMPEL BioSolutions, Amytrx Therapeutics, AnGes MG, Animal Allergy Clinical Laboratories, Anokion, Anthem Bluecross, Antibe Therapeutics, AntibioTx, Antidote, AOBiome Therapeutics, Applied Biology, Applied BioMath, Aptar Pharma, Aptorum Group, Aptuit, Arbor Biotechnologies, Arch Biopartners, Arctic Vision, Arcutis Biotherapeutics, Arena Pharmaceuticals, argenx, Aristea Therapeutics, Ark Biosciences, Arrien Pharmaceuticals, Artisan Bio, Artizan Biosciences, ASKA Pharmaceuticals, AskAt, Aslan Pharma, Aspect Biosystems, Assembly Biosciences, Astellas Pharma, Asthma UK, AstraZeneca, Astria Therapeutics, Atara Biotherapeutics, Athos Therapeutics, Attwill Medical Solutions, aTyr Pharma, Aurinia Pharmaceuticals, Australasian Gastro Intestinal Research Foundation, Autobahn Therapeutics, Autolus, Avacta, Avalere Health, Avicanna, Axela, AXIM Biotechnologies, Axoltis Pharma, Axsome Therapeutics, Azenta Life Sciences, Azitra, Bachem, Back-A-Line, Basilea Pharmaceutica, Bausch & Lomb, Bausch Health Companies, Baxalta, Bayer, Baylor Health Care System, Bazelet, BCD Bioscience, BDD Pharma, Beijing InnoCare Pharma, Beijing Tianshi Tongda Pharmaceuticals Technology, Beijing Tide Pharmaceutical, Belharra Therapeutics,, BenevolentAI, Bennu Pharmaceuticals, Beyondspring Pharmaceuticals, BGI, Bigfoot Biomedical, Bill and Melinda Gates Foundation, BinnoPharm, Bio-Cancer Treatment International, Bio-Gate, Bio-Path, Bio-Rad Laboratories, Bio-Techne, Bio-Thera Solutions, biOasis Technologies, BioClinica, Biocon, Biodexa Pharmaceuticals, Biofourmis, Biogen, Biohaven Pharmaceuticals, Biolojic Design, BiomeBank, BioMed X Innovation Center, Biomica, BiomX, BiondVax, BioNova Pharmaceuticals, BioNxt Solutions, Bioprojet, Bioqube Ventures, BioRap Technologies, BioSenic, BioSense Global, Bird Foundation, Blue Cross Blue Shield Association, BlueRock Therapeutics, Blue Shield of California, Boehringer Ingelheim, Boragen, Boston Pharmaceuticals, Boston University School of Medicine, Brain Canada, Brainomix, BrainStorm Cell Therapeutics, Brand Institute, Breakthrough Health, Brickell Biotech, Bridge Biotherapeutics, Brigham and Women's Hospital, BrightInsight, Bristol-Myers Squibb, British Lung Foundation, Brown University, C4X Discovery, Cabaletta Bio, Cadila Pharmaceuticals, Caladrius Biosciences, California Institute for Biomedical Research, California Institute for Regenerative Medicine, California Institute of Technology, Calliditas Therapeutics, Calypso Biotech, Cambridge Enterprise, Cam Med, Can-Fite BioPharma, Cannassure Therapeutics, Cantargia, Cara Therapeutics, CareFirst BlueCross BlueShield, Carna BioSciences, Carnegie Mellon University, Casebia Therapeutics, CASI Pharmaceuticals, Cassie + Friends, Catalyst Pharmaceuticals, Catholic University Leuven, Cedars-Sinai Medical Center, Celgene, Celiac Disease Foundation, Cellerys, Celltrion, Celmatix, Cel Sci, Celsius Therapeutics, Center for Genomic Regulation, Centessa Pharmaceuticals, Central Institute for Experimental Animals, Centre for Drug Research and Development (CDRD), Centurion, Century Therapeutics, Changchun High & New Technology Industries, Charite-Universitatsmedizin, Charite Universitatsmedizin Berlin, CheckPoint Immunology, Chelexa Biosciences, Chiesi Farmaceutici, Children's Hospital Boston, China Medical System, Chinese University of Hong Kong, Chugai Pharmaceutical, CHU Sainte-Justine, Cicero Diagnostics, Cincinnati Children’s Hospital Medical Center, Cipla, Circassia, Citrine Medicine, Clarify Medical, Clearside Biomedical, Clene Nanomedicine, Cleveland Clinic, ClinConnect, Clinical Enterprise, Clinical Ink, CMS Aesthetics, CMS Medical, Cochin Hospital, Coeptis Therapeutics, Coherus Biosciences, Collplant, Columbia University, Conduit Pharmaceuticals, ConSynance Therapeutics, Contineum Therapeutics, Convelo Therapeutics, Cook Biotech, COPD Foundation, Corbin Therapeutics, Corbus Pharmaceuticals, Cornell University, Corrona, Cosmofix, COUR Pharmaceutical, Coya Therapeutics, Creative Medical Technologies, CRISPR Therapeutics, Critical Path Institute (C-Path), Crohn's and Colitis Foundation of America, CR Pharma, CRS Bio, Cryostem, CrystalGenomics, CSL Behring, CSPC Pharmaceutical Group, CS Pharmaceuticals, Cue Biopharma, Cugene, Cumberland Pharmaceuticals, Curable, Curant Health, Cynata Therapeutics, Cyrus Biotechnology, Cytocom, CytoReason, Cyxone, Daewoong Pharmaceutical, Daiichi Sankyo, Dalriada Drug Discovery, Dalton Pharma Services, Danuo Science Group, DayTwo, Debiopharm, Decode Health, Defymed, Delphi Genetics, Delta 4, Denali Therapeutics, Department of Defense, Dermavant Sciences, Dermira, DermTech, DevPro Biopharma, DexCom, Diabeloop, Diabetes Research Connection, Diamyd Medical, Diomics, Diurnal, Diversigen, DNAnexus, Dong-A ST, Dr. Falk Pharma, Dr. Reddy's Laboratories, Dragonfly Therapeutics, Draper Laboratories, DreaMed Diabetes, Duke Clinical Research Institute (DCRI), Duke University, DyDo Pharma, DynamiCure Biotechnology, EA Pharma, EffRx Pharmaceuticals, EGeen, Eisai, Eisai Inc, Eleven Biotherapeutics, Eli Lilly, ElsaLys Biotech, Emendo Biotherapeutics, Enable Biosciences, Encore Dermatology, Endo International, Engitix, Enosi Therapeutics, Entera Health, Enteris Biopharma, Enterome Bioscience, Entos Pharmaceuticals, Enzene Biosciences, EOFlow, Epicore Biosystems, epitoMAP, Epivax, Equillium, Erasmus University Medical Center, Ethos Research & Development, Ethypharm, Everest Medicines, Evidation Health, Evive Biotechnology, Evolve BioSystems, Evommune, EVOQ Therapeutics, Evotec, Ewopharma, Exagen Diagnostics, Excelra, Exicure, Experimental Therapeutics Centre of Singapore, ExScientia, EyePoint Pharmaceuticals, FairJourney Biologics, Fast Forward, Federal Ministry of Health (Germany), Feinstein Institute for Medical Research, Ferring Pharmaceuticals, Fibrocor Therapeutics, Fibrogen, Finch Therapeutics, Find Therapeutics, Fission Labs LATAM, Fluidigm, Food and Drug Administration (FDA), Foresee Pharmaceuticals, Forward Pharma, Fosun Pharmaceutical, Foundation for Celiac Disease Outcome Measures, Foundation for Sarcoidosis Research, Four H, Fred Hutchinson Cancer Research Center, French National Institute for Agricultural Research, Frequency Therapeutics, Fresenius Kabi Pharmaceuticals, FSD Pharma, Fujifilm, FUJIFILM Cellular Dynamics, Fujifilm Diosynth Biotechnologies, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Fundacion Progreso y Salud, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, G42 Healthcare, Galapagos, Galderma, GC Biopharma, Gedeon Richter, GenEdit, Genentech, Geneoscopy, Generex Biotechnology, Genetic Analysis, Genmab, Genomics, Genovis, Genprex, GenScript ProBio, Genten Therapeutics, GentiBio, Genzyme, Georgetown University, George Washington University, Georgiamune, Georgia State University, Giiant Pharma, Gilead Sciences, Ginkgo BioWorks, GI Reviewers, Glenmark Pharmaceuticals, GoodRx, Gossamer Bio, GPCR Therapeutics, Graviton Bioscience, Green Park Collaborative, GRI Bio, GSK, Guangzhou Institute of Respiratory Disease, Gusto Global, Gynica, Hadasit Bioholdings, Hadassah Medical Center, Halozyme Therapeutics, HanAll Pharmaceuticals, Hangzhou Highlightll Pharmaceutical, Hangzhou Zhongmei Huadong Pharmaceutical, Hannover Medical School, Hansa Biopharma, Haplogen, Happify Health, HAPPYneuron, Harbour Biomed, Harmony Biosciences, Harvard Stem Cell Institute, Harvard University, Harvest Capital Strategies, HCmed Innovations, HealthPrize Technologies, Helius Medical Technologies, Hesperos, HIBio, HiFiBio, Highland Therapeutics, Highmark Health, Hikma Pharmaceuticals, Hoffmann La Roche, Honeywell, Hope Medicine, Horizon Pharma plc, Horizon Therapeutics, Hospital for Special Surgery, Hoth Therapeutics, HotSpot Therapeutics, Huadong Medicine, Hudson Institute of Medical Research, Humacyte, Humanetics, Humanigen, I-mab, Iagnosis, IASO Biotherapeutics, IBM, Icahn School of Medicine at Mount Sinai, Ichnos Sciences, Iconovo, Idorsia, IFM Therapeutics, Illumina, ILTOO Pharma, ImaginAb, Imagine Pharmaceuticals, Imbio, Imcyse, Imeka, IMIDomics, Immetas Therapeutics, ImmPACT Bio, Immugenyx, ImmunArray, ImmuneID, Immune Pharmaceuticals, Immune Therapeutics, ImmuNext, Immunic, ImmunogenX, Immunomic Therapeutics, Immunovia, Inception Sciences, Incyte, InDex Pharmaceuticals, Indiana University, Industrial Technology Research Institute, Inexia, Inmagene Biopharmaceuticals, Innate Pharma, Innodem Neurosciences, Innovate Biopharmaceuticals, Innovate UK, Innovation Pharmaceuticals, Innovative Health Diagnostics, Innovent Biologics, Inotrem, Inovalon, Inserm Transfert, InSilicoTrials, Insmed Inc, Institute for Genome Statistics and Bioinformatics, Institute of Endocrinology, Metabolism, and Reproduction, Institute of Human Genetics, Institut Gustave Roussy, Instituto de Ciencias Farmaceuticas, Institut Pasteur, Intas Pharmaceuticals, Integral Molecular, Intellia Therapeutics, Intract Pharma, Intrexon, Inventiva, Ionis Pharmaceuticals, IONTAS, IQVIA, Ironwood Pharmaceuticals, ISD Immunotech, Italian Multiple Sclerosis Society, Iterative Scopes, iTolerance, Izana Bioscience, Jackson Laboratory, Janssen Biotech, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Sciences, Japan Tobacco, Jazz Pharmaceuticals, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu QYuns Therapeutics, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Consumer Companies, Johnson & Johnson Innovation, JSR, Jubilant Radiopharma, Jubilant Therapeutics, Juntendo University, Jupiter Wellness, Juvenile Diabetes Research Foundation, JW Pharmaceutical, JW Therapeutics, Kadimastem, Kadmon Pharmaceuticals, Kaken Pharmaceutical, Kaleido Biosciences, Kamada, KangWon University Institute of Medical Science, Karolinska Institute, KBI BioPharma, Keck School of Medicine of USC, Keio Gijuku University, Kenneth Rainin Foundation (KRF), Kezar Life Sciences, Kindeva Drug Delivery, King's College Hospital, Kiniksa Pharmaceuticals, Kissei Pharmaceutical, Kite Pharma, Klue, Koneksa Health, Koye Pharmaceuticals, Kubota Vision, KYE Pharmaceuticals, Kyowa Hakko Kirin, Kyverna Therapeutics, Lahey Hospital & Medical Center, La Jolla Institute for Allergy & Immunology, Landos Biopharma, Lassen Therapeutics, Laurel Venture Capital, Leona M and Harry B Helmsley Charitable Trust, LEO Pharma, Les Laboratoires Servier, Lexicon Pharmaceuticals, LGC, LianBio, LifeArc, Ligand Pharmaceuticals, Lipidor, LMU University Hospital Munich, London School of Medicine and Dentistry, Lonza, Lubeck Institute of Experimental Dermatology, Lucid Psycheceuticals, Luminary Therapeutics, Lumir Lab, Lung Biotechnology, Lupin, Lupus Canada, Lupus Foundation of America (LFA), Lupus Research Alliance, Lupus Therapeutics, Lurie Children's Hospital of Chicago, Lyfebulb, LyGenesis, Lynk Pharmaceuticals, MaaT Pharma, Mabwell Bioscience, mAbXience, Mallinckrodt Pharmaceuticals, Mapi Pharma, Marinomed Biotechnologie, Maruho, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, Mass General Brigham, Max-Planck, Max Biopharma, Maxion Therapeutics, Mayo Clinic, MC2 Therapeutics, MC10, McGill University, McMaster University, MD Anderson Cancer Center, MDNA Life Sciences, Medac, Medexus Pharmaceuticals, Medgenics, Medical International Research, Medical University of Graz, Medical University of South Carolina, Medical University of Vienna, Medical University South Carolina, Medicines Discovery Catapult, Medimetriks, MedImmune, Medison Pharma, MedRhythms, Medsenic, Meiji Seika, Melior Pharmaceuticals, Menarini, Menarini Asia-Pacific, Merck and Co, Metaba, Metabolon, Metrion Biosciences, Microba Life Sciences, Microbio Shanghai, Microbiotica, Microdrop, Mimetas, MiTest Health, Mitsubishi Tanabe Pharma, Molecular Stethoscope, Molnlycke Health Care, Momenta Pharmaceuticals, Monash University, MoonLake Immunotherapeutics, Morphic Therapeutic, MorphoSys, Mor Research Applications, Mount Sinai Medical Center, Multiple Sclerosis Society of Canada, Mundipharma, Mylan Laboratories, Mylan Pharmaceuticals, Myovant Sciences, Myriad Genetics, NanoString Technologies, Napo Pharmaceuticals, National Eczema Association, National Health Service, National Heart, Lung and Blood Institute, National Institute for Environmental Health Sciences, National Institute for Health and Care Research Respiratory Translational Research Collaboration, National Institute of Allergy and Infectious Diseases, National Institute of Arthritis and Musculoskeletal Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institutes of Health, National Kidney Foundation, National Organization for Rare Disorders, National Psoriasis Foundation, National Science Foundation, Navidea Biopharmaceuticals, Nektar Therapeutics, Neogap Therapeutics, Neoteryx, Neovacs, Neovii Pharmaceuticals, Nestle Health Science, Neuraxpharm, Neurodon, NeuroGenesis, Nexel, Neximmune, Nima, Nimbus Therapeutics, Ningbo Tai Kang Medical Technology, Nitto Denko, Nkarta Therapeutics, NLS Pharmaceutics, Nordic Pharma Group, North Carolina State University, Northwestern University, North Zealand University Hospital, Novartis, Novome Biotechnologies, Novo Nordisk, Nuance Pharma, Nuevolution, Numares, NuMedii, Nutra Pharma, NYU Langone Medical Center, Oak Hill Bio, Ocumension Therapeutics, Oklahoma Medical Research Foundation, OliX Pharmaceuticals, Oncocross, One GI, Oneness Biotech, Ono Pharmaceutical, Optimeos Life Sciences, Or-Genix Therapeutics, Orange Grove Bio, Orexia Therapeutics, Orion, OSE Immunotherapeutics, Oslo University Hospital, Ospedale San Raffaele, Ossium Health, Otsuka, Ovation, OWC Pharmaceutical Research, Paladin Labs, Palisade Bio, Panaxia, Pancryos, Pandion Therapeutics, Panorama Research, Pantherna Therapeutics, Paragon Bioservices, Parexel Biotech, Parvus Therapeutics, Patara Pharma, PathoQuest, Patient-Centered Outcomes Research Institute, PEAR Therapeutics, Pediatric Dermatology Research Alliance, Pediatrix Therapeutics, Pelle Ventures, Penn State College of Medicine, Pfizer, Pharmanovia, Pharmapark, Phebra, Pheno Therapeutics, Philips, PicnicHealth, PlantEXT, Pluristem Therapeutics, Polpharma, Popit, Portal Instruments, PPD, Pragma Bio, Precision BioSciences, Precision Image Analysis, PredictImmune, Principia Biopharma, Priovant Therapeutics, Procyon Technologies, Progenity, Progentec Diagnostics, Prometheus Biosciences, Prometheus Laboratories, Promius Pharma, Propeller Health, ProQR Therapeutics, Protagen, Protagonist Therapeutics, Protalix BioTherapeutics, Protxx, Provention Bio, Pulmonary Fibrosis Foundation (PFF), Purdue Pharma, Purnovate, PvP Biologics, Q32 Bio, Quadri Pharmaceuticals, Qu Biologics, Queen Mary University of London, Queensland Institute of Medical Research (QIMR), Queensland University of Technology, Quell Therapeutics, Quest Diagnostics, Quoin Pharmaceuticals, Quotient, Quotient Clinical, Rafa Pharmaceuticals, Ramot at Tel Aviv University, Rani Therapeutics, Recipharm, RedHill Biopharma, Redx Pharma, Regen BioPharma, Regeneron Genetics Center, Regeneron Pharmaceuticals, Regentys, Regranion, Relife, Remedium Bio, Renovion, Repertoire Immune Medicines, ReproCell, Reset Therapeutics, Resilia Pharmaceuticals, RespirAI Medical, RespireRx Pharmaceuticals, Revive Therapeutics, Revon Systems, ReWalk Robotics, Rheos Medicines, Rigel Pharmaceuticals, RION, Rochal Industries, Roche, Roivant Sciences, Royal College of Surgeons (Ireland), RS BioTherapeutics, Rubedo Life Sciences, SAB Biotherapeutics, Salix Pharmaceuticals, Samsung Bioepis, Samsung Biologics, Samumed, Sandoz, Sanguine, Sanofi, Sanofi US Services, Sano Genetics, Sanpellegrino Cosmetics, SarcoMed USA, Satisfai Health, SATT Conectus Alsace, SATT Lutech, Savana, Schneider Children's Medical Center, Scholar Rock, Schrodinger, SciCann Therapeutics, Science 37, Scienion, Scipher Medicine, Scleroderma Research Foundation, Seattle Children's Hospital, Seattle Childrens Research Institute, Second Genome, Sedec Therapeutics, Seelos Therapeutics, Selecta Biosciences, Selexis, Semma Therapeutics, Sengenics, Seres Therapeutics, Sernova, Serosep, SFC Fluidics, Shanghai Ark Biopharmaceutical, Shaperon, Sheba Medical Center, Shepherd Center, Shire Laboratories, Shire Pharmaceuticals, SHL Medical, Siemens Healthineers, Sigilon Therapeutics, Signum Biosciences, Silence Therapeutics, Simcere Pharmaceuticals, Sirion Biotech, Sitryx, Skyhawk Therapeutics, SomaLogic, Sonde Health, Sonoma BioTherapeutics, Sorrento Therapeutics, Sosei Heptares, Sourcia, Spesana, Spiral Therapeutics, Spring Bank Pharmaceuticals, SQI Diagnostics, STADA Arzneimittel, Standigm, Stanford University, Stanford University School of Medicine, Statera Biopharma, Stony Brook University, Strados Labs, Strainprint Technologies, Structural Genomics Consortium, Sumitomo Pharmaceuticals, Sunovion Pharmaceuticals, Sun Pharmaceutical, SUNY Upstate Medical University, Suzhou Connect Biopharmaceuticals, Suzhou Porton Advanced Solutions, Symbiotix Biotherapies, SynAct Pharma, Synaptogenix, Syndax Pharmaceuticals, Synlogic, Synthekine, Synthonics, Systems Oncology, Taiho, Takara Bio, Takeda Pharmaceutical, TARGET PharmaSolutions, Tavotek Biotherapeutics, Tel Aviv Sourasky Medical Center, Temedica, Tetragenetics, Teva Pharmaceutical Industries, Teva Pharmaceuticals USA, Texas A&M University, TFF Pharmaceuticals, TG Therapeutics, The Alfred Hospital, The Consortium of Rheumatology Researchers of North America, The Crohn's and Colitis Foundation of Canada, The Multiple Sclerosis Association of America, Theradiag, Theramex, Theravance, The Vancouver Island Health Authority, Three Lakes Foundation, Thunderbolt Pharma, TiGenix, Tissium, TiumBio, Tiziana Life Sciences, TONIX Pharmaceuticals, Topas Therapeutics, Torii Pharmaceutical, toSense, Tow Foundation, Transpire, Trethera, True Diagnostics, True North Therapeutics, Truveta, TScan Therapeutics, Tsinghua University, Twist Bioscience, twoXAR, TxCell, UCB, UGA Biopharma, UNION Therapeutics, United Therapeutics, Universite Laval, University Gastroenterology, University Gottingen, University Health Network, University Hospital of Leuven, University Libre of Brussels, University of Adelaide, University of Alberta, University of Barcelona, University of Birmingham, University of Bonn, University of British Columbia, University of Calgary, University of California, San Diego, University of California Berkeley, University of California Irvine, University of California San Francisco, University of Chicago, University of Cincinnati, University of Connecticut, University of Erlangen, University of Florida, University of Houston, University of Illinois, University of Manitoba, University of Maryland, University of Massachusetts, University of Miami, University of Michigan, University of Minnesota, University of North Carolina, University of North Texas Health Science Center, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Sheffield, University of Sherbrooke, University of South Australia, University of Texas at El Paso, University of Texas Southwestern Medical Center, University of Toronto, University of Utah, University of Virginia, University of Washington, University of Western Ontario, University of Windsor, University of Wisconsin-Madison, University of Zurich, Upsher-Smith, US Army Medical Research Institute of Chemical Defense, Utrecht University, Vaccinex, Valeant Pharmaceuticals, Vanderbilt University, Vasomune Therapeutics, Vcell Healthcare, Vectura, Vedanta Biosciences, Velocity Pharmaceutical Development, Veracyte, Verily, Verona Pharma, Versant Ventures, Vertex Pharmaceuticals, Vestibular Disorders Association, ViaCyte, Viatris, Vicore Pharma, Victoria University, Viela Bio, Vifor-Fresenius Medical Care Renal Pharma, Viome, Virgo Surgical Video Solutions, Vitalli Bio, Vital Therapies, Vium, Voronoi, Voyager Therapeutics, vTv Therapeutics, Wanchunbulin, Weill Cornell Medical College, WellDyne, White Rock Capital Partners, William Harvey Research Instutute, W L Gore, Worldwide Clinical Trials, Wuhan Kindstar Diagnostics, WuXi Biologics, Wyss Institute, Xbrane Bioscience, Xencor, XL-Protein, XtalPi, Xycrobe Therapeutics, Xylyx Bio, Yale School of Medicine, Yale University, Yangtze River Pharmaceutical Group, ZappRx, Zedira, Zenas BioPharma, Zenoaq, Zenyaku Kogyo, Zura Bio, Zylo Therapeutics, Zymeworks, ZyVersa Therapeutics

Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.

Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.

Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.

Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.

The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.

Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant

Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document

All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.

Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.